Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 16/20 | 0.60 |
| ▸ | ERBB2 | P04626 | 15/20 | 0.60 |
| ▸ | GAK | O14976 | 1/20 | 0.57 |
| ▸ | ERBB4 | Q15303 | 2/20 | 0.55 |
| ▸ | ABL1 | P00519 | 1/20 | 0.52 |
| ▸ | INSR | P06213 | 1/20 | 0.52 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.52 |
| ▸ | CDK2 | P24941 | 1/20 | 0.52 |
| ▸ | PLK1 | P53350 | 1/20 | 0.52 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.52 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.52 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2478975 | 1.00 | EGFR (0.60) | EGFRERBB2GAKERBB4ABL1 | |
| SCHEMBL2478977 | 1.00 | EGFR (0.60) | EGFRERBB2GAKERBB4ABL1 | |
| SCHEMBL29651885 | 1.00 | EGFR (0.60) | EGFRERBB2GAKERBB4ABL1 | |
| SCHEMBL9973641 | 0.93 | ERBB2 (0.61) | EGFRERBB2GAKERBB4ABL1 | |
| SCHEMBL20436802 | 0.92 | EGFR (0.65) | EGFRERBB2GAKERBB4ABL1 | |
| SCHEMBL3698690 | 0.92 | EGFR (0.62) | EGFRERBB2GAKERBB4ABL1 | |
| SCHEMBL29651886 | 0.92 | EGFR (0.62) | EGFRERBB2GAKERBB4ABL1 | |
| SCHEMBL3698693 | 0.92 | EGFR (0.62) | EGFRERBB2GAKERBB4ABL1 | |
| SCHEMBL6959360 | 0.92 | EGFR (0.62) | EGFRERBB2GAKERBB4ABL1 | |
| SCHEMBL9975240 | 0.91 | EGFR (0.64) | EGFRERBB2GAKERBB4ABL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9951051-B2 | Process for producing alkynylketone derivative | SHIONOGI & CO., LTD. (JP) | 2018-04-24 | — | — | US | disclosed |
| US-9951051-B2 | Process for producing alkynylketone derivative | SHIONOGI & CO., LTD. (JP) | 2018-04-24 | — | — | US | disclosed |
| US-20170197943-A1 | PROCESS FOR PRODUCING ALKYNYLKETONE DERIVATIVE | SHIONOGI & CO., LTD. (JP) | 2017-07-13 | — | — | US | disclosed |
| US-20170197943-A1 | PROCESS FOR PRODUCING ALKYNYLKETONE DERIVATIVE | SHIONOGI & CO., LTD. (JP) | 2017-07-13 | — | — | US | disclosed |
| WO-2015182682-A1 | METHOD FOR PRODUCING ALKYNYL KETONE DERIVATIVE | 塩野義製薬株式会社 | 2015-12-03 | — | — | WO | disclosed |
| US-8426589-B2 | Process for production of quinazoline derivative | SHIONOGI & CO., LTD. (JP) | 2013-04-23 | — | — | US | disclosed |
| US-8426589-B2 | Process for production of quinazoline derivative | SHIONOGI & CO., LTD. (JP) | 2013-04-23 | — | — | US | disclosed |
| US-8349857-B2 | Quinazoline derivatives having tyrosine kinase inhibitory activity | SHIONOGI & CO., LTD. (JP) | 2013-01-08 | — | — | US | disclosed |
| US-8202879-B2 | Quinazoline derivatives having tyrosine kinase inhibitory activity | SHIONOGI & CO., LTD. (JP) | 2012-06-19 | — | — | US | disclosed |
| US-20120123114-A1 | QUINAZOLINE DERIVATIVES HAVING TYROSINE KINASE INHIBITORY ACTIVITY | SHIONOGI & CO., LTD. (JP) | 2012-05-17 | — | — | US | disclosed |
| US-20110257391-A1 | PROCESS FOR PRODUCTION OF QUINAZOLINE DERIVATIVE | SHIONOGI & CO., LTD. (JP) | 2011-10-20 | — | — | US | disclosed |
| US-20110257391-A1 | PROCESS FOR PRODUCTION OF QUINAZOLINE DERIVATIVE | SHIONOGI & CO., LTD. (JP) | 2011-10-20 | — | — | US | disclosed |
| US-20090143414-A1 | Quinazoline Derivatives Having Tyrosine Kinase Inhibitory Activity | SHIONOGI & CO., LTD. (JP) | 2009-06-04 | — | — | US | disclosed |
| EP-1854789-A1 | QUINAZOLINE DERIVATIVE HAVING TYROSINE KINASE INHIBITORY ACTIVITY | SHIONOGI & CO., LTD. (JP) | 2007-11-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110257391-A1 | PROCESS FOR PRODUCTION OF QUINAZOLINE DERIVATIVE | ABL1, MAP2K5, MAP2K2 | EGFR 213/4885ERBB2 42/4885GAK 255/4885 |
| US-20090143414-A1 | Quinazoline Derivatives Having Tyrosine Kinase Inhibitory Activity | ERBB2, EGFR, ABL1 | EGFR 2/4885ERBB2 1/4885GAK 340/4885 |
| US-20120123114-A1 | QUINAZOLINE DERIVATIVES HAVING TYROSINE KINASE INHIBITORY ACTIVITY | ERBB2, EGFR, ABL1 | EGFR 2/4885ERBB2 1/4885GAK 340/4885 |
| US-20170197943-A1 | PROCESS FOR PRODUCING ALKYNYLKETONE DERIVATIVE | PDK4, PDK3, PDK2 | EGFR 650/4885ERBB2 458/4885GAK 84/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.